Search | Biogen

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

Biogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference

Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

Aducanumab Update Presentation

Aducanumab Update Presentation 946.6 KB

Biogen Reports Q3 2019 Revenues of $3.6 Billion

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

Form 8-K